✦ LIBER ✦

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

✍ Scribed by Castro, J E; Sandoval-Sus, J D; Bole, J; Rassenti, L; Kipps, T J

Book ID: 109886573
Publisher: Nature Publishing Group
Year: 2008
Tongue: English
Weight: 159 KB
Volume: 22
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2008.214

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab in combination with high-dose

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia

✍ Castro, J E; James, D F; Sandoval-Sus, J D; Jain, S; Bole, J; Rassenti, L; Kipps 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 412 KB

Rituximab in combination with high-dose

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia

✍ Rassenti, L; Kipps, T J; Castro, J E; James, D F; Sandoval-Sus, J D; Jain, S; Bo 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 56 KB

Early treatment of high-risk chronic lym

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

✍ Clive S. Zent; Timothy G. Call; Tait D. Shanafelt; Renee C. Tschumper; Diane F. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB

## Abstract ## BACKGROUND. Patients with chronic lymphocytic leukemia (CLL) usually are treated only for progressive disease. However, the discovery of biologic predictors of a high risk of disease progression, together with the development of newer, more targeted therapies, could change this para

Serum globulins as marker of immune rest

Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia

✍ Doru T. Alexandrescu; Peter H. Wiernik 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 324 KB

Enhancing the action of rituximab by add

Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia

✍ Wei Xu; Kou-Rong Miao; Dan-Xia Zhu; Cheng Fang; Hua-Yuan Zhu; Hua-Jie Dong; Dong 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 280 KB

## Abstract Complement deficiencies have been identified in many chronic lymphocytic leukemia (CLL) patients. Supplying fresh frozen plasma (FFP)‐derived complement can enhance complement‐dependent cell lysis by the rituximab. The objective of our study was to evaluate the clinical efficacy and saf

Mitoxantrone and high-dose cytosine arab

Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia

✍ Hagop M. Kantarjian; Ronald L. Walters; Michael J. Keating; Elihu H. Estey; SUSA 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 2 views

Twenty-five adult patients with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside 3 g/m2 intravenously over 2 hours every 12 hours for six doses. Overall, nine patients (36%) achieved complete